Related Experiment Video
Updated: Jan 17, 2026
10:16
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
13.6K
BRAF V600E liquid biopsy-based detection in precision oncology
Gabriela R Mendeluk1, Verónica A Alonso2
1Departamento de Bioquímica Clínica, Hospital de Clínicas"José de San Martín". Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica- INFIBIOC, C.A.B.A, Argentina.
Advances in Laboratory Medicine
|September 22, 2025
Summary
The BRAF V600E mutation is crucial in precision oncology, found in various cancers. Liquid biopsy offers a less invasive method for detecting this mutation, aiding treatment and monitoring.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The BRAF V600E mutation is a key genetic alteration in precision oncology.
- This mutation is prevalent in multiple cancer types, including melanoma, colorectal, and thyroid cancers.
- Liquid biopsy presents a minimally invasive approach for detecting this mutation.
Purpose of the Study:
- To review the molecular biology of the BRAF V600E mutation.
- To explore its role in tumor progression and its diagnostic, prognostic, and therapeutic utility.
- To highlight liquid biopsy screening options and their advantages over traditional solid biopsies.
Main Methods:
- Review of existing literature on BRAF V600E.
- Analysis of molecular biology, tumor progression, and clinical utility.
- Comparison of liquid biopsy versus solid biopsy for mutation detection.
Main Results:
- Liquid biopsy provides a less invasive alternative to tissue biopsies for BRAF V600E detection.
- This method shows potential for guiding treatment adjustments and monitoring patient response.
- The review details the mutation's role in various tumor types.
Conclusions:
- Liquid biopsy for BRAF V600E detection is poised for widespread clinical adoption.
- This approach can optimize cancer patient monitoring and personalize treatment strategies.
- The findings support enhanced disease management through minimally invasive genetic testing.
